Medical Isotopes Global Market Report 2026

Medical isotopes are radioisotopes utilized in medicine, emitting positrons or gamma rays for diagnostic purposes. These isotopes aid in visualizing and targeting specific tissues or abnormalities within the body, facilitating tasks such as evaluating heart function, assessing blood flow to the heart muscle, and diagnosing coronary artery disease.

The main product types of medical isotopes comprise stable isotopes and radioisotopes. Stable isotopes are versions of chemical elements that do not decay over time, retaining their atomic structure indefinitely. Production methods for medical isotopes include neutron activation, cyclotrons, nuclear reactors, and others. These isotopes find applications in nuclear therapy, equipment radioactive sources, and diagnostic procedures. End users of medical isotopes include hospitals, diagnostic centers, and research institutes.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs have affected the medical isotopes market by increasing costs related to imported nuclear materials, specialized equipment, and isotope processing components essential for medical applications. These impacts are most evident in diagnostic and therapeutic isotope supply chains across north america, europe, and asia pacific, where cross border movement of radioactive materials is tightly regulated. Higher costs and logistical delays have challenged timely isotope availability for hospitals and diagnostic centers. Conversely, tariffs have driven investments in domestic production facilities, cyclotron installations, and localized supply networks, improving long term supply security and healthcare resilience.

The medical isotopes market research report is one of a series of new reports from The Business Research Company that provides medical isotopes market statistics, including medical isotopes industry global market size, regional shares, competitors with a medical isotopes market share, detailed medical isotopes market segments, market trends and opportunities, and any further data you may need to thrive in the medical isotopes industry. This medical isotopes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The medical isotopes market size has grown strongly in recent years. It will grow from $7.26 billion in 2025 to $7.79 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to established use of technetium 99m in diagnostics, expansion of hospital nuclear medicine departments, growth in cancer diagnosis rates, reliance on nuclear reactors for isotope supply, advances in medical imaging equipment.

The medical isotopes market size is expected to see strong growth in the next few years. It will grow to $10.05 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to increasing prevalence of chronic diseases, rising demand for targeted radiotherapy, investment in cyclotron infrastructure, growth of personalized medicine, technological advancements in isotope production methods. Major trends in the forecast period include rising use of radioisotopes in diagnostic imaging, growing adoption of nuclear medicine therapies, increasing demand for precision oncology treatments, expansion of cyclotron based isotope production, higher focus on short lived isotope supply chains.

The rising cancer and heart disease rates are expected to propel the growth of the medical isotope market going forward. Cancer and heart disease rates refer to how frequently these conditions occur and persist within a population over a given period, reflecting broader public health patterns and the effectiveness of prevention strategies. The increasing prevalence of these diseases is linked to modern sedentary lifestyles driven by technology use and desk-based occupations, which reduce physical activity levels. Medical isotopes play a critical role in diagnosing and treating cancer and heart disease through imaging modalities such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), as well as in therapeutic applications including radiation therapy and radioactive stents. For instance, in August 2024, according to Macmillan Cancer Support, more than 3 million people in the UK were living with cancer, a number projected to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, rising cancer and heart disease rates are driving the growth of the medical isotope market.

Major companies in the medical isotope market are focusing on strategic collaborations to strengthen their competitive position. Strategic collaborations involve formal partnerships between organizations to pursue shared goals and deliver mutually beneficial outcomes. For example, in September 2023, International Isotopes Inc., a US-based medical technology company, partnered with Phantech Medical, a US-based biomedical hardware manufacturer, to integrate solutions for their customers. Through this collaboration, the companies aim to transform the calibration and reference sources market for pre-clinical imaging by designing, manufacturing, and distributing innovative sealed sources that support medical imaging and theranostics applications.

In April 2024, Telix Pharmaceuticals Limited, an Australia-based biopharmaceutical company, acquired ARTMS Inc. for an undisclosed amount. This acquisition provides Telix with enhanced access to ARTMS' cutting-edge radiopharmaceutical production technologies, strengthening its capabilities in developing and commercializing targeted radiopharmaceuticals for cancer imaging and therapy. ARTMS Inc. is a Canada-based medical equipment manufacturer specializing in technologies that improve the production of diagnostic imaging isotopes.

Major companies operating in the medical isotopes market are Rosatom State Atomic Energy Corporation, Bayer AG, Siemens Healthineers AG, GE HealthCare, Urenco Ltd., Lantheus Holdings Inc., Curium Pharma, Canadian Nuclear Laboratories, Eckert & Ziegler Strahlen- und Medizintechnik AG., Advanced Accelerator Applications a Novartis company, Nordion Inc., NTP Radioisotopes SOC Ltd., The Institute for Radioelements (IRE), NorthStar Medical Radioisotopes LLC, Isotopen Technologien Munchen AG (ITM), EczacIbasI-Monrol Nuclear Products Co., SHINE Medical Technologies LLC, Blue Earth Diagnostics Limited, Isologic Innovative Radiopharmaceuticals, IBA Radiopharma Solutions, Izotop, Coqui RadioPharmaceuticals Corp., Jubilant DraxImage Inc.

North America was the largest region in the medical isotopes market in 2025. The regions covered in the medical isotopes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the medical isotopes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The medical isotopes market consists of sales of technetium-99m, carbon-11, and gallium-68 which serve specific purposes in medical diagnosis and therapy. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Medical Isotopes Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses medical isotopes market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for medical isotopes ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The medical isotopes market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product Type: Diagnostic Radioisotopes; Therapeutic Radioisotopes; Theranostic Radioisotopes
• 2) By Production Method: Neutron Activation; Cyclotron; Nuclear Reactor; Other Production Method
• 3) By Application: Diagnostic Imaging; Targeted Radionuclide Therapy; Brachytherapy; Radiopharmaceutical Research & Development
• 4) By End Use: Hospitals; Diagnostic Imaging Centers; Research Institutes
• Subsegments:
• 1) By Diagnostic Radioisotopes: Technetium-99m; Fluorine-18; Gallium-68; Iodine-123; Carbon-11; Other Diagnostic Radioisotopes
• 2) By Therapeutic Radioisotopes: Iodine-131; Lutetium-177; Yttrium-90; Strontium-89; Samarium-153; Actinium-225; Other Therapeutic Radioisotopes
• 3) By Theranostic Radioisotopes: Gallium-68 / Lutetium-177 Pairs; Copper-64 / Copper-67 Pairs; Iodine-123 / Iodine-131 Pairs; Scandium-44 / Scandium-47 Pairs; Terbium Isotope Pairs; Other Theranostic Radioisotopes
• Companies Mentioned: Rosatom State Atomic Energy Corporation; Bayer AG; Siemens Healthineers AG; GE HealthCare; Urenco Ltd.; Lantheus Holdings Inc.; Curium Pharma; Canadian Nuclear Laboratories; Eckert & Ziegler Strahlen- und Medizintechnik AG.; Advanced Accelerator Applications a Novartis company; Nordion Inc.; NTP Radioisotopes SOC Ltd.; The Institute for Radioelements (IRE); NorthStar Medical Radioisotopes LLC; Isotopen Technologien Munchen AG (ITM); EczacIbasI-Monrol Nuclear Products Co.; SHINE Medical Technologies LLC; Blue Earth Diagnostics Limited; Isologic Innovative Radiopharmaceuticals; IBA Radiopharma Solutions; Izotop; Coqui RadioPharmaceuticals Corp.; Jubilant DraxImage Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.